Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aldesleukin + pembrolizumab
- Development stage
- Phase 2
- Lead developer
- Merck
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
aldesleukin + pembrolizumab is a combination therapy being investigated by Emory University for the treatment of previously untreated, PD-L1 positive, stage IV non-small cell lung cancer (NSCLC). This regimen combines low-dose aldesleukin, a recombinant form of the cytokine interleukin-2 (IL-2) that promotes T-cell proliferation and activation, with pembrolizumab, a monoclonal antibody that inhibits the PD-1/PD-L1 checkpoint pathway. The combination aims to synergistically enhance the anti-tumor immune response by reinvigorating exhausted T cells and promoting an effector-like phenotype, potentially improving clinical outcomes in patients with high PD-L1 expression.
- Other names
- Low-dose IL-2 + pembrolizumabIL-2 + pembrolizumab
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on aldesleukin + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aldesleukin + pembrolizumab.